Skip to content

Neos started at buy by Cantor

August 1, 2017

Cantor Fitzgerald initiates coverage on Neos Therapeutics (NASDAQ: NEOS) with a Overweight rating and a price target of $20.00.

Analyst Louis Chen comments “The sales potential of Neos’s ADHD platform is underappreciated, in our view. We think continued success with the Adzenys XR-ODT sales, the launch of Cotempla XR-ODT in the fall and approval of Amphetamine XR oral suspension ~9/15/17, will drive upwards earningsrevisions and Neos’s stock higher. We do not think Neos needs any more capital raises to reach profitability.”


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: